Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926180 | 0.88 | LMNA (0.48) | LMNAHPGDATMPOLBTP53 | |
| SCHEMBL4030921 | 0.87 | TRPA1 (0.49) | LMNAHPGDATMPOLBTP53 | |
| SCHEMBL4033863 | 0.84 | LMNA (0.45) | LMNAHPGDATMPOLBTP53 | |
| SCHEMBL4032575 | 0.83 | TRPA1 (0.46) | LMNAHPGDTP53L3MBTL1PTGER3 | |
| SCHEMBL926737 | 0.78 | LMNA (0.46) | LMNAPOLBMAPTPTGER3PKM | |
| SCHEMBL4030551 | 0.78 | LMNA (0.40) | LMNAATMPOLBTP53L3MBTL1 | |
| SCHEMBL926215 | 0.77 | PSEN1 (0.51) | ALDH1A1NPSR1 | |
| SCHEMBL926976 | 0.77 | HSD11B1 (0.46) | LMNAL3MBTL1MAPTPTGER3PKM | |
| SCHEMBL926719 | 0.77 | MMP8 (0.51) | POLBALDH1A1NPSR1 | |
| SCHEMBL4844597 | 0.77 | MMP8 (0.44) | POLBMAPTPTGER3ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | LMNA 1943/4885HPGD 3316/4885ATM 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.